Stockreport

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]

DBV Technologies S.A. - American Depositary Shares  (DBVT) 
US:NASDAQ Investor Relations: dbv-technologies.com/en/investor-relations
PDF VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified thr [Read more]